Biofrontera Reports Full Year 2018 Financial Results
April 29, 2019 02:00 ET
|
Biofrontera AG
Leverkusen, Germany, April 29, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera AG to hold extraordinary shareholders’ meeting on 15 May 2019
April 26, 2019 09:20 ET
|
Biofrontera AG
Leverkusen, Germany, April 26, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced in...
Biofrontera reports further positive results from the phase III trial with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
April 16, 2019 07:30 ET
|
Biofrontera AG
Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Biofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results
April 16, 2019 05:30 ET
|
Biofrontera AG
Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing...
Biofrontera reports preliminary unaudited sales revenue for the first three months of 2019
April 15, 2019 06:15 ET
|
Biofrontera AG
Leverkusen, Germany, April 15, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Changes in the composition of the Supervisory Board
March 27, 2019 09:05 ET
|
Biofrontera AG
Leverkusen, Germany, March 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the...
Biofrontera provides corporate update; conference call details for March 26, 2019
March 25, 2019 11:30 ET
|
Biofrontera AG
Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a...
PROCESSA PHARMACEUTICALS ANNOUNCES UP-LISTING TO OTCQB MARKET
December 06, 2018 09:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
FPMI Restructures CardioPET License With Massachusetts General Hospital
September 27, 2018 09:00 ET
|
FluoroPharma Medical, Inc.
MONTCLAIR, NJ, Sept. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that it has reached an agreement with The General Hospital Corporation,...
HOVERINK BIOTECHNOLOGIES APPOINTS VSTOCK TRANSFER, LLC AS ITS TRANSFER AGENT AND REGISTRAR
July 11, 2018 10:24 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, July 11, 2018 (GLOBE NEWSWIRE) -- HOVERINK BIOTECHNOLOGIES Appoints VSTOCK TRANSFER, LLC as its TRANSFER AGENT AND REGISTRAR Hoverink Biotechnologies is currently developing IV and...